Analysts Expect vTv Therapeutics Inc. (VTVT) Will Post Quarterly Sales of $200,000.00
Brokerages forecast that vTv Therapeutics Inc. (NASDAQ:VTVT) will report sales of $200,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for vTv Therapeutics’ earnings, with the highest sales estimate coming in at $200,000.00 and the lowest estimate coming in at $190,000.00. vTv Therapeutics reported sales of $40,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 400%. The business is scheduled to report its next earnings results on Wednesday, November 1st.
According to Zacks, analysts expect that vTv Therapeutics will report full year sales of $200,000.00 for the current financial year, with estimates ranging from $200,000.00 to $30.43 million. For the next year, analysts expect that the business will report sales of $15.10 million per share, with estimates ranging from $200,000.00 to $30.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.02. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.19 million.
Several research firms have issued reports on VTVT. Zacks Investment Research lowered shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a research report on Wednesday, July 5th. Canaccord Genuity restated a “buy” rating and issued a $15.00 price target on shares of vTv Therapeutics in a research report on Friday, August 4th. Five investment analysts have rated the stock with a buy rating, vTv Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $14.45.
vTv Therapeutics (NASDAQ VTVT) opened at 5.37 on Thursday. vTv Therapeutics has a 52 week low of $4.65 and a 52 week high of $7.50. The stock’s market cap is $52.05 million. The firm’s 50 day moving average price is $5.51 and its 200-day moving average price is $5.90.
In other news, major shareholder Ronald O. Perelman acquired 10,000 shares of the stock in a transaction on Wednesday, August 16th. The shares were purchased at an average cost of $4.97 per share, for a total transaction of $49,700.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Ronald O. Perelman acquired 50,000 shares of the stock in a transaction on Tuesday, August 15th. The shares were purchased at an average price of $4.72 per share, for a total transaction of $236,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 165,000 shares of company stock worth $728,150. Corporate insiders own 0.80% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in vTv Therapeutics by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 1,305 shares in the last quarter. Renaissance Technologies LLC grew its position in vTv Therapeutics by 4.8% during the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock worth $418,000 after purchasing an additional 2,900 shares in the last quarter. State Street Corp grew its position in vTv Therapeutics by 2.1% during the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after purchasing an additional 1,976 shares in the last quarter. Ameriprise Financial Inc. grew its position in vTv Therapeutics by 62.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock worth $1,313,000 after purchasing an additional 101,850 shares in the last quarter. Finally, Sphera Funds Management LTD. grew its position in vTv Therapeutics by 50.0% during the 1st quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock worth $1,965,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 11.05% of the company’s stock.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.